<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells and in curing severe combined immunodeficient mice with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents </plain></SENT>
<SENT sid="2" pm="."><plain>The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> or <z:chebi fb="0" ids="28445">vincristine</z:chebi> is effective </plain></SENT>
<SENT sid="3" pm="."><plain>The in-vivo experiments using HD37-dgRTA with <z:chebi fb="0" ids="28445">vincristine</z:chebi> prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days) </plain></SENT>
<SENT sid="4" pm="."><plain>Also, 80% of the mice treated with IT plus <z:chebi fb="0" ids="28445">vincristine</z:chebi> were long-term survivors </plain></SENT>
</text></document>